Stem, Inc. Announces At-the-Market Equity Offering: Key Investor Insights

Stem, Inc. has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC), announcing critical developments that could have a significant impact on shareholders and the company’s future share price. Below, we outline the main points and what investors need to know.

Key Points from the Report

• At-the-Market Equity Program: Stem, Inc. has entered into a Sales Agreement allowing the company to issue and sell shares of its common stock from time to time through an appointed sales agent, up to an aggregate maximum program amount as set forth in the agreement.
• Legal Opinion Filed: The company has filed the legal opinion of Gibson, Dunn & Crutcher LLP as Exhibit 5 to the Form 8-K, confirming the validity of the shares to be sold under the program.
• Use of Proceeds: Funds raised will not result in the company being classified as an investment company under the Investment Company Act of 1940, and will be used as described in the prospectus.
• Compliance and Reporting: The company confirms ongoing compliance with all SEC filing requirements, including timely filings of all required reports and disclosures under the Securities Exchange Act.
• Financial Integrity: The financial statements filed and incorporated by reference have been audited by Deloitte & Touche LLP, an independent registered public accounting firm. The company asserts the accuracy and reliability of its financial reporting and internal controls.
• Share Listing and Liquidity: Shares will remain listed on the New York Stock Exchange or any other principal market, and the company affirms ongoing compliance with all applicable listing requirements.
• No Material Litigation: Other than as disclosed, there are no pending or threatened legal, governmental, or regulatory proceedings that would reasonably be expected to result in a material adverse change for the company.
• No Price Stabilization or Manipulation: The company and its subsidiaries have confirmed that they have not taken any actions to manipulate or stabilize the price of their shares or other securities in violation of Regulation M.
• Forward-Looking Statements: The company has included forward-looking statements in the prospectus, each accompanied by cautionary statements regarding factors that could cause actual results to differ materially.

Details Investors Need to Know

• Potential Impact on Share Price and Dilution:
  • By authorizing the sale of additional common shares in the open market, this program can provide Stem, Inc. with flexibility to raise capital as needed.
  • However, the issuance of new shares may result in dilution for existing shareholders, which can be price-sensitive and could impact share value, especially depending on the size, timing, and market conditions of the sales.
• Legal and Compliance Safeguards:
  • The legal opinion from Gibson, Dunn & Crutcher LLP affirms the shares to be issued are valid, fully paid, and non-assessable, provided the registration statement remains effective and shares are sold in accordance with the board’s authorization.
  • The company maintains that all regulatory and legal requirements are being met, including the prompt filing of amendments or supplements to the prospectus if material events arise.
• Ongoing Disclosure and Investor Communication:
  • Stem, Inc. will provide quarterly disclosures on the number of shares sold and the net proceeds received, either in quarterly or annual reports, or through prospectus supplements.
  • The company has committed to keeping investors informed of any material events, including potential suspensions, delistings, or regulatory actions affecting the shares.
• Risk Factors:
  • Investors should be aware of potential risks, including market volatility, dilution, and any unforeseen legal or regulatory developments, though no such issues are reported as pending or imminent at this time.

Conclusion

The at-the-market equity program represents a significant development for Stem, Inc. and its investors. The ability to issue new shares provides the company with a flexible tool for capital raising, but also introduces potential dilution risk. Investors should monitor future disclosures from the company regarding the pace, size, and proceeds of any share sales under this program, as well as any market or regulatory developments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The information presented is based on publicly available filings and may not reflect the most current developments. Stem, Inc. may make additional filings or announcements that could affect the matters discussed herein.

View STEM, INC. Historical chart here